The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Assessing increased creatinine levels in patient with lung cancer receiving TKIs
Monica Chen, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reports on patients with lung cancer having false decreases in renal function as a result of receiving tyrosine kinase inhibitors (TKIs) such as selpercatinib and entrectinib. Increased levels of creatinine as a result of these TKIs were found to cause this phenomenon, and alternative markers of renal function that do not affect creatinine levels include cystatin C. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
